FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2487180529> ?p ?o ?g. }

• W2487180529 endingPage "1977" @default.
• W2487180529 startingPage "1971" @default.
• W2487180529 abstract "Essentials•Men have an unexplained higher risk of a first and recurrent venous thrombosis (VT) than women.•We studied the role of the major European Y chromosome haplogroups in first and recurrent VT.•In contrast to a study on coronary artery disease, haplogroup I was not linked to VT risk.•Haplogroup E‐carriers may have an increased risk of recurrent VT, but a larger study is needed.Summary: BackgroundThe risk of venous thrombosis (VT) recurrence is higher in men than in women. When reproductive risk factors are excluded, this sex difference is also apparent for a first VT. The current explanations for this difference are insufficient.ObjectivesTo study the association between chromosome Y haplogroups and the risks of a first and recurrent VT.MethodsY chromosomes of 3742 men (1729 patients; 2013 controls) from the MEGA case–control study were tracked into haplogroups according to the phylogenetic tree. We calculated the risk of a first VT by comparing the major haplogroups with the most frequent haplogroup. For recurrence risk, 1645 patients were followed for a mean of 5 years, during which 350 developed a recurrence (21%; MEGA follow‐up study). We calculated recurrence rates for the major haplogroups, and compared groups by calculating hazard ratios.ResultsWe observed 13 haplogroups, of which R1b was the most frequent (59%). The major haplogroups were not associated with a first VT, with odds ratios ranging from 1.01 to 1.15. Haplogroup E carriers had the highest recurrence rate (53.5 per 1000 person‐years, 95% confidence interval [CI] 33.3–86.1), whereas haplogroup R1a carriers had the lowest recurrence rate (24.3 per 1000 person‐years, 95% CI 12.6–46.6). As compared with haplogroup R1b carriers, both haplogroups were not significantly associated with recurrence risk.ConclusionsIn contrast to a study on coronary artery disease, our results do not show a clear predisposing effect of Y haplogroups on first and recurrent VT risk in men. It is therefore unlikely that Y variation can explain the sex difference in VT risk. Essentials•Men have an unexplained higher risk of a first and recurrent venous thrombosis (VT) than women.•We studied the role of the major European Y chromosome haplogroups in first and recurrent VT.•In contrast to a study on coronary artery disease, haplogroup I was not linked to VT risk.•Haplogroup E‐carriers may have an increased risk of recurrent VT, but a larger study is needed. •Men have an unexplained higher risk of a first and recurrent venous thrombosis (VT) than women.•We studied the role of the major European Y chromosome haplogroups in first and recurrent VT.•In contrast to a study on coronary artery disease, haplogroup I was not linked to VT risk.•Haplogroup E‐carriers may have an increased risk of recurrent VT, but a larger study is needed. The risk of venous thrombosis (VT) recurrence is higher in men than in women. When reproductive risk factors are excluded, this sex difference is also apparent for a first VT. The current explanations for this difference are insufficient. To study the association between chromosome Y haplogroups and the risks of a first and recurrent VT. Y chromosomes of 3742 men (1729 patients; 2013 controls) from the MEGA case–control study were tracked into haplogroups according to the phylogenetic tree. We calculated the risk of a first VT by comparing the major haplogroups with the most frequent haplogroup. For recurrence risk, 1645 patients were followed for a mean of 5 years, during which 350 developed a recurrence (21%; MEGA follow‐up study). We calculated recurrence rates for the major haplogroups, and compared groups by calculating hazard ratios. We observed 13 haplogroups, of which R1b was the most frequent (59%). The major haplogroups were not associated with a first VT, with odds ratios ranging from 1.01 to 1.15. Haplogroup E carriers had the highest recurrence rate (53.5 per 1000 person‐years, 95% confidence interval [CI] 33.3–86.1), whereas haplogroup R1a carriers had the lowest recurrence rate (24.3 per 1000 person‐years, 95% CI 12.6–46.6). As compared with haplogroup R1b carriers, both haplogroups were not significantly associated with recurrence risk. In contrast to a study on coronary artery disease, our results do not show a clear predisposing effect of Y haplogroups on first and recurrent VT risk in men. It is therefore unlikely that Y variation can explain the sex difference in VT risk." @default.
• W2487180529 created "2016-08-23" @default.
• W2487180529 creator A5018038275 @default.
• W2487180529 creator A5031487360 @default.
• W2487180529 creator A5053215549 @default.
• W2487180529 creator A5057672552 @default.
• W2487180529 creator A5070612975 @default.
• W2487180529 date "2016-10-01" @default.
• W2487180529 modified "2023-09-30" @default.
• W2487180529 title "Male‐specific risk of first and recurrent venous thrombosis: a phylogenetic analysis of the Y chromosome" @default.
• W2487180529 cites W1493666455 @default.
• W2487180529 cites W1516646446 @default.
• W2487180529 cites W1953541770 @default.
• W2487180529 cites W1968143178 @default.
• W2487180529 cites W1970261618 @default.
• W2487180529 cites W1975167661 @default.
• W2487180529 cites W1976120710 @default.
• W2487180529 cites W1984083837 @default.
• W2487180529 cites W1997126970 @default.
• W2487180529 cites W2007086823 @default.
• W2487180529 cites W2032884716 @default.
• W2487180529 cites W2047438580 @default.
• W2487180529 cites W2068993942 @default.
• W2487180529 cites W2073700468 @default.
• W2487180529 cites W2076507560 @default.
• W2487180529 cites W2078075583 @default.
• W2487180529 cites W2085404943 @default.
• W2487180529 cites W2095430126 @default.
• W2487180529 cites W2100283122 @default.
• W2487180529 cites W2102778065 @default.
• W2487180529 cites W2104810995 @default.
• W2487180529 cites W2108659951 @default.
• W2487180529 cites W2113104073 @default.
• W2487180529 cites W2113530759 @default.
• W2487180529 cites W2116679740 @default.
• W2487180529 cites W2129839379 @default.
• W2487180529 cites W2139092465 @default.
• W2487180529 cites W2144938250 @default.
• W2487180529 cites W2149892026 @default.
• W2487180529 cites W2169550506 @default.
• W2487180529 cites W2314873497 @default.
• W2487180529 cites W2324325959 @default.
• W2487180529 cites W2707883 @default.
• W2487180529 cites W4249053801 @default.
• W2487180529 doi "https://doi.org/10.1111/jth.13437" @default.
• W2487180529 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27495181" @default.
• W2487180529 hasPublicationYear "2016" @default.
• W2487180529 type Work @default.
• W2487180529 sameAs 2487180529 @default.
• W2487180529 citedByCount "5" @default.
• W2487180529 countsByYear W24871805292017 @default.
• W2487180529 countsByYear W24871805292019 @default.
• W2487180529 countsByYear W24871805292022 @default.
• W2487180529 countsByYear W24871805292023 @default.
• W2487180529 crossrefType "journal-article" @default.
• W2487180529 hasAuthorship W2487180529A5018038275 @default.
• W2487180529 hasAuthorship W2487180529A5031487360 @default.
• W2487180529 hasAuthorship W2487180529A5053215549 @default.
• W2487180529 hasAuthorship W2487180529A5057672552 @default.
• W2487180529 hasAuthorship W2487180529A5070612975 @default.
• W2487180529 hasBestOaLocation W24871805291 @default.
• W2487180529 hasConcept C104317684 @default.
• W2487180529 hasConcept C126322002 @default.
• W2487180529 hasConcept C156957248 @default.
• W2487180529 hasConcept C164705383 @default.
• W2487180529 hasConcept C180754005 @default.
• W2487180529 hasConcept C197754878 @default.
• W2487180529 hasConcept C201526758 @default.
• W2487180529 hasConcept C207103383 @default.
• W2487180529 hasConcept C2780011451 @default.
• W2487180529 hasConcept C2780868729 @default.
• W2487180529 hasConcept C44249647 @default.
• W2487180529 hasConcept C50440223 @default.
• W2487180529 hasConcept C54355233 @default.
• W2487180529 hasConcept C71924100 @default.
• W2487180529 hasConcept C86803240 @default.
• W2487180529 hasConceptScore W2487180529C104317684 @default.
• W2487180529 hasConceptScore W2487180529C126322002 @default.
• W2487180529 hasConceptScore W2487180529C156957248 @default.
• W2487180529 hasConceptScore W2487180529C164705383 @default.
• W2487180529 hasConceptScore W2487180529C180754005 @default.
• W2487180529 hasConceptScore W2487180529C197754878 @default.
• W2487180529 hasConceptScore W2487180529C201526758 @default.
• W2487180529 hasConceptScore W2487180529C207103383 @default.
• W2487180529 hasConceptScore W2487180529C2780011451 @default.
• W2487180529 hasConceptScore W2487180529C2780868729 @default.
• W2487180529 hasConceptScore W2487180529C44249647 @default.
• W2487180529 hasConceptScore W2487180529C50440223 @default.
• W2487180529 hasConceptScore W2487180529C54355233 @default.
• W2487180529 hasConceptScore W2487180529C71924100 @default.
• W2487180529 hasConceptScore W2487180529C86803240 @default.
• W2487180529 hasIssue "10" @default.
• W2487180529 hasLocation W24871805291 @default.
• W2487180529 hasLocation W24871805292 @default.
• W2487180529 hasOpenAccess W2487180529 @default.
• W2487180529 hasPrimaryLocation W24871805291 @default.
• W2487180529 hasRelatedWork W1493666455 @default.
• W2487180529 hasRelatedWork W2022392719 @default.

• next